Skip to main content
. 2014 Jun 5;10(8):2295–2302. doi: 10.4161/hv.29233

Table 6. Oral immunotherapy trial using anti-IgE treatment.

Study Treatment N Age Dose Achieved on Initial Escalation Day (mg protein)
Nadeau (2011)60 Omalizumab + Milk OIT 11 7–17 y 9/11 (82%) reached 1000 mg
(1992mg cumulative dose)
Schneider (2013)65 Omalizumab + Peanut OIT 13 7–15 y 13/13 (100%) reached 500mg
(992mg cumulative dose)
Bégin (2014)39 Omalizumab + Multiple Allergen OIT 25 4–15 y 19/25 (76%) reached 1250mg in total (2380 mg cumulative dose)